Evidence map›Paper›PMID 42639828›Full record

ArticleJournal of medical virology2026

Enhanced Immunogenicity and Cross-Neutralizing Activity of a Trivalent Adenoviral Vector-Based SARS-CoV-2 Vaccine in Mice.

Jianhua Li, Wanchen Song, Jiaxuan Li, Ruofan Peng, Chenghao Chen, Yanjun Zhang, Yonglan Zhu, Keda Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jianhua LiDepartmentof Microbiology, Zhejiang Key Laboratory of Public Health Detection and Pathogenesis Research, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.ORCID https://orcid.org/0000-0002-9216-4699
Wanchen SongJiaxing Center for Disease Control and Prevention, Jiaxing, China.
Jiaxuan LiKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
Ruofan PengSchool of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, China.
Chenghao ChenSchool of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, China.
Yanjun ZhangDepartmentof Microbiology, Zhejiang Key Laboratory of Public Health Detection and Pathogenesis Research, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Yonglan ZhuDepartment of the Center for Basic and Translational Research, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Keda ChenSchool of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, China.ORCID https://orcid.org/0000-0002-9469-0991

Funding

Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences 2022-I2M-CoV19-006National Natural Science Foundation of China U20A20410University-Level Scientific Research Project of Zhejiang Shuren University 2024R057
6 · The paper itself

Abstract

The emergence of diverse SARS-CoV-2 Omicron subvariants has reduced the efficacy of existing vaccines, highlighting the need for multivalent vaccines with broader neutralizing capacity. We developed a trivalent adenoviral vector-based vaccine (Ad5-CoV19-prototype/Delta/BF.7) encoding the spike proteins of the ancestral strain, Delta variant, and Omicron BF.7 strain, and evaluated its immunogenicity in BALB/c mice. Four- to 6-week-old female BALB/c mice were intramuscularly immunized with 10 µg of monovalent or trivalent vaccines using single-dose or two-dose (2-week interval) regimens. Neutralizing antibody (nAb) titers against the ancestral strain, Omicron BA.5, and XBB.1.5, as well as IFN-γ

Indexed as

Antibodies, NeutralizingCOVID-19COVID-19 VaccinesImmunogenicity, VaccineSARS-CoV-2AdenoviridaeAnimalsAntibodies, ViralCross ReactionsFemaleGenetic VectorsHumansInterferon-gammaMiceMice, Inbred BALB CSpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesInterferon-gammaSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Ad5BF.7SARS‐CoV‐2trivalentviral infection

Identifiers

PMID42639828
PMCPMC13504691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.